Literature DB >> 20675495

Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production.

Michelle Merrigan1, Anilrudh Venugopal, Michael Mallozzi, Bryan Roxas, V K Viswanathan, Stuart Johnson, Dale N Gerding, Gayatri Vedantam.   

Abstract

Toxigenic Clostridium difficile strains produce two toxins (TcdA and TcdB) during the stationary phase of growth and are the leading cause of antibiotic-associated diarrhea. C. difficile isolates of the molecular type NAP1/027/BI have been associated with severe disease and hospital outbreaks worldwide. It has been suggested that these "hypervirulent" strains produce larger amounts of toxin and that a mutation in a putative negative regulator (TcdC) allows toxin production at all growth phases. To rigorously explore this possibility, we conducted a quantitative examination of the toxin production of multiple hypervirulent and nonhypervirulent C. difficile strains. Toxin gene (tcdA and tcdB) and toxin gene regulator (tcdR and tcdC) expression was also monitored. To obtain additional correlates for the hypervirulence phenotype, sporulation kinetics and efficiency were measured. In the exponential phase, low basal levels of tcdA, tcdB, and tcdR expression were evident in both hypervirulent and nonhypervirulent strains, but contrary to previous assumptions, toxin levels were below the detectable thresholds. While hypervirulent strains displayed robust toxin production during the stationary phase of growth, the amounts were not significantly different from those of the nonhypervirulent strains tested; further, total toxin amounts were directly proportional to tcdA, tcdB, and tcdR gene expression. Interestingly, tcdC expression did not diminish in stationary phase, suggesting that TcdC may have a modulatory rather than a strictly repressive role. Comparative genomic analyses of the closely related nonhypervirulent strains VPI 10463 (the highest toxin producer) and 630 (the lowest toxin producer) revealed polymorphisms in the tcdR ribosome binding site and the tcdR-tcdB intergenic region, suggesting that a mechanistic basis for increased toxin production in VPI 10463 could be increased TcdR translation and read-through transcription of the tcdA and tcdB genes. Hypervirulent isolates produced significantly more spores, and did so earlier, than all other isolates. Increased sporulation, potentially in synergy with robust toxin production, may therefore contribute to the widespread disease now associated with hypervirulent C. difficile strains.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20675495      PMCID: PMC2944552          DOI: 10.1128/JB.00445-10

Source DB:  PubMed          Journal:  J Bacteriol        ISSN: 0021-9193            Impact factor:   3.490


  40 in total

1.  Emergence of Clostridium difficile toxinotype III, PCR-ribotype 027-associated disease, France, 2006.

Authors:  B Coignard; F Barbut; K Blanckaert; J M Thiolet; I Poujol; A Carbonne; J C Petit; J C Desenclos
Journal:  Euro Surveill       Date:  2006-09-14

2.  First isolation of Clostridium difficile 027 in Japan.

Authors:  H Kato; Y Ito; R J van den Berg; E J Kuijper; Y Arakawa
Journal:  Euro Surveill       Date:  2007-01-11

3.  An epidemic, toxin gene-variant strain of Clostridium difficile.

Authors:  L Clifford McDonald; George E Killgore; Angela Thompson; Robert C Owens; Sophia V Kazakova; Susan P Sambol; Stuart Johnson; Dale N Gerding
Journal:  N Engl J Med       Date:  2005-12-01       Impact factor: 91.245

4.  A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Québec.

Authors:  Bruno Hubert; Vivian G Loo; Anne-Marie Bourgault; Louise Poirier; André Dascal; Elise Fortin; Marc Dionne; Manon Lorange
Journal:  Clin Infect Dis       Date:  2006-12-06       Impact factor: 9.079

5.  Comparative phylogenomics of Clostridium difficile reveals clade specificity and microevolution of hypervirulent strains.

Authors:  R A Stabler; D N Gerding; J G Songer; D Drudy; J S Brazier; H T Trinh; A A Witney; J Hinds; B W Wren
Journal:  J Bacteriol       Date:  2006-10       Impact factor: 3.490

6.  tcdC genotypes associated with severe TcdC truncation in an epidemic clone and other strains of Clostridium difficile.

Authors:  Scott R Curry; Jane W Marsh; Carlene A Muto; Mary M O'Leary; A William Pasculle; Lee H Harrison
Journal:  J Clin Microbiol       Date:  2006-10-11       Impact factor: 5.948

7.  Construction and analysis of chromosomal Clostridium difficile mutants.

Authors:  Jennifer R O'Connor; Dena Lyras; Kylie A Farrow; Vicki Adams; David R Powell; Jason Hinds; Jackie K Cheung; Julian I Rood
Journal:  Mol Microbiol       Date:  2006-09       Impact factor: 3.501

8.  Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates.

Authors:  Thomas Akerlund; Bo Svenungsson; Asa Lagergren; Lars G Burman
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

9.  Clinical features of Clostridium difficile-associated infections and molecular characterization of strains: results of a retrospective study, 2000-2004.

Authors:  Frédéric Barbut; Béatrice Gariazzo; Laetitia Bonné; Valérie Lalande; Béatrice Burghoffer; Ralucca Luiuz; Jean-Claude Petit
Journal:  Infect Control Hosp Epidemiol       Date:  2007-01-24       Impact factor: 3.254

10.  Rapid, accurate, computational discovery of Rho-independent transcription terminators illuminates their relationship to DNA uptake.

Authors:  Carleton L Kingsford; Kunmi Ayanbule; Steven L Salzberg
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

View more
  124 in total

1.  Clostridium difficile carriage in elderly subjects and associated changes in the intestinal microbiota.

Authors:  Mary C Rea; Orla O'Sullivan; Fergus Shanahan; Paul W O'Toole; Catherine Stanton; R Paul Ross; Colin Hill
Journal:  J Clin Microbiol       Date:  2011-12-07       Impact factor: 5.948

2.  Lack of association between clinical outcome of Clostridium difficile infections, strain type, and virulence-associated phenotypes.

Authors:  Stéphanie Sirard; Louis Valiquette; Louis-Charles Fortier
Journal:  J Clin Microbiol       Date:  2011-09-28       Impact factor: 5.948

3.  Tigecycline suppresses toxin A and B production and sporulation in Clostridium difficile.

Authors:  Michael John Aldape; Dustin Delaney Heeney; Amy Evelyn Bryant; Dennis Leroy Stevens
Journal:  J Antimicrob Chemother       Date:  2014-08-23       Impact factor: 5.790

Review 4.  Genome Editing of Food-Grade Lactobacilli To Develop Therapeutic Probiotics.

Authors:  Jan-Peter van Pijkeren; Rodolphe Barrangou
Journal:  Microbiol Spectr       Date:  2017-09

5.  Evaluation of growth and sporulation of a non-toxigenic strain of Clostridioides difficile (Z31) and its shelf viability.

Authors:  Carlos Augusto Oliveira Júnior; Rodrigo Otávio Silveira Silva; Diogo Soares Gonçalves Cruz; Isadora Honorato Pires; Guilherme Guerra Alves; Francisco Carlos Faria Lobato
Journal:  Braz J Microbiol       Date:  2018-12-18       Impact factor: 2.476

6.  Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection.

Authors:  Alexa R Weingarden; Chi Chen; Aleh Bobr; Dan Yao; Yuwei Lu; Valerie M Nelson; Michael J Sadowsky; Alexander Khoruts
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-11-27       Impact factor: 4.052

7.  A novel subtyping assay for detection of Clostridium difficile virulence genes.

Authors:  Stephanie L Angione; Aartik A Sarma; Aleksey Novikov; Leah Seward; Jennifer H Fieber; Leonard A Mermel; Anubhav Tripathi
Journal:  J Mol Diagn       Date:  2014-01-13       Impact factor: 5.568

8.  The C-Terminal Domain of Clostridioides difficile TcdC Is Exposed on the Bacterial Cell Surface.

Authors:  Ana M Oliveira Paiva; Leen de Jong; Annemieke H Friggen; Wiep Klaas Smits; Jeroen Corver
Journal:  J Bacteriol       Date:  2020-10-22       Impact factor: 3.490

9.  Decreasing Clostridium difficile infections by an antimicrobial stewardship program that reduces moxifloxacin use.

Authors:  Judith Maria Wenisch; Susanne Equiluz-Bruck; Marta Fudel; Ingun Reiter; Andrea Schmid; Erna Singer; Andreas Chott
Journal:  Antimicrob Agents Chemother       Date:  2014-06-16       Impact factor: 5.191

10.  Effects of ciprofloxacin on the expression and production of exotoxins by Clostridium difficile.

Authors:  Michael John Aldape; Aaron Eugene Packham; Drew William Nute; Amy Evelyn Bryant; Dennis Leroy Stevens
Journal:  J Med Microbiol       Date:  2013-02-21       Impact factor: 2.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.